Chemistry:Levonadifloxacin
From HandWiki
Levonadifloxacin (trade name Emrok) is an antibiotic drug of the fluoroquinolone class.[1][2] Chemically, it is the (S)-enantiomer of the racemic drug nadifloxacin.
It is approved in India for the treatment of skin and soft tissue infections of Gram-positive bacteria.[3] It is also being studied for potential use against resistant strains of bacteria including Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis.[4]
Levonadifloxacin has poor oral bioavailability. A prodrug of levonadifloxacin with high oral bioavailability, alalevonadifloxacin, has been developed to mitigate this problem.[5]
References
- ↑ "Levonadifloxacin, a Novel Benzoquinolizine Fluoroquinolone, Modulates Lipopolysaccharide-Induced Inflammatory Responses in Human Whole-Blood Assay and Murine Acute Lung Injury Model". Antimicrobial Agents and Chemotherapy 64 (5). April 2020. doi:10.1128/aac.00084-20. PMID 32152077.
- ↑ "Levonadifloxacin, a recently approved benzoquinolizine fluoroquinolone, exhibits potent in vitro activity against contemporary Staphylococcus aureus isolates and Bengal Bay clone isolates collected from a large Indian tertiary care hospital". The Journal of Antimicrobial Chemotherapy 75 (8): 2156–2159. August 2020. doi:10.1093/jac/dkaa142. PMID 32361727.
- ↑ "Levonadifloxacin". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800016734.
- ↑ "Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence". Drug Design, Development and Therapy 13: 4351–4365. 2019. doi:10.2147/DDDT.S229882. PMID 31920285.
- ↑ "Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection". Bioorganic & Medicinal Chemistry Letters 54. December 2021. doi:10.1016/j.bmcl.2021.128432. PMID 34757217.
 |  |
